Dr. Anderson on Superoxide Dismutase Mimetic GC4419 in Treating Patients With Oropharyngeal Carcinoma

Carryn Anderson, MD
Published: Friday, Sep 09, 2016



Carryn Anderson, MD, assistant professor of Radiation Oncology, University of Iowa, discusses a phase Ib/IIa study of superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavitiy or oropharyngeal carcinoma.

Superoxide dismutase mimetic GC4419 is a drug with a mechanism that rapidly and selectively converts superoxide to hydrogen peroxide. According to Anderson, this is important because superoxide contributes to the downstream cascade of oral mucositis that occurs in patients receiving radiation therapy. The drug's mechanism actually mimics enzymes that already naturally occur in the body.

As a result, normal tissues are protected from radiation-induced superoxide burst that occurs whenever patients are treated with chemoradiation, explains Anderson.


Carryn Anderson, MD, assistant professor of Radiation Oncology, University of Iowa, discusses a phase Ib/IIa study of superoxide dismutase mimetic GC4419 to reduce chemoradiotherapy-induced oral mucositis in patients with oral cavitiy or oropharyngeal carcinoma.

Superoxide dismutase mimetic GC4419 is a drug with a mechanism that rapidly and selectively converts superoxide to hydrogen peroxide. According to Anderson, this is important because superoxide contributes to the downstream cascade of oral mucositis that occurs in patients receiving radiation therapy. The drug's mechanism actually mimics enzymes that already naturally occur in the body.

As a result, normal tissues are protected from radiation-induced superoxide burst that occurs whenever patients are treated with chemoradiation, explains Anderson.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x